Clinical Report: CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis

Overview

Engineered CAR T cells targeting TNF demonstrated long-lasting disease control in a mouse model of rheumatoid arthritis.

Background

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the presence of tumor necrosis factor (TNF), which plays a significant role in disease pathogenesis. Current anti-TNF biologics require repeated administration, which can lead to reduced efficacy due to anti-drug antibody formation.

Data Highlights

No numerical data or trial data presented in the source material.

Key Findings

• Engineered CAR T cells (TNFR1TIF) effectively captured and degraded TNF in a mouse model.
• A single infusion of TNFR1TIF cells reduced serum human TNF to near wild-type levels.
• Treated mice showed prevention and treatment of rheumatoid arthritis-like disease comparable to repeated high-dose adalimumab.
• The CAR T cells persisted in peripheral blood for up to one year without lymphodepleting preconditioning.
• Safety experiments indicated no significant disruption of endogenous T cell homeostasis or organ structure over 12 months.
• The approach may be adaptable to target other soluble inflammatory mediators beyond TNF.

Clinical Implications

Further research is needed to evaluate the long-term safety and efficacy of this approach.

Conclusion

Future studies are required to assess its applicability in human patients.

Related Resources & Content

1. Min Peng et al., Tsinghua University, 2023 -- CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis
2. Clinical Rheumatology — The Role of CAR-T Cell Therapy in Systemic Sclerosis Management
3. Frontiers in Immunology — Antibody targeting of the TNF–TNFR2 axis to overcome tumor immune resistance
4. Journal of Crohn's and Colitis — Chimeric Antigen Receptor Tregs Targeting IL-23R in Crohn’s Disease: The Emergence of a New Era in Cellular Immunotherapy?
5. Journal of Crohn's and Colitis — IL23R-Specific CAR Tregs for the Treatment of Crohn’s Disease
6. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
7. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study
8. Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma | Rheumatology | Oxford Academic